Idiopathic myelofibrosis: pathogenesis to treatment.
Idiopathic myelofibrosis (IMF) is the least common of the chronic myeloproliferative disorders and carries the worst prognosis with a median survival of 4 years. It is a clonal haematopoietic stem-cell disorder and, although the pathogenesis remains unclear, approximately 50% of cases are known to possess an activating JAK2 V617F mutation. In contrast, the characteristic stromal proliferation is a reactive, or secondary, event that results from the aberrant release of a variety of growth factors from megakaryocytes and monocytes. Treatment for most cases is supportive, although androgens, recombinant erythropoietin, steroids and thalidomide are effective modalities for the amelioration of anaemia. Myelosuppression, splenectomy and irradiation are valuable therapeutic modalities for specific clinical situations. Prognostic scores are available to aid the identification of cases for whom bone marrow transplantation should be considered. Recently, the use of reduced intensity conditioning has resulted in prolonged survival and lower transplant-related mortality. This review summarises the recent advances in the disease's pathogenesis and discusses the role of the various therapeutic options.
Academic Unit of Haematology, Division of Genomic Medicine, Royal Hallamshire Hospital, Sheffield, UK. j.t.reily@sheffield.ac.uk
John T
JT
Reilly
D000740:Anemia / Q000209:etiology / Q000628:therapy; D016207:Cytokines / Q000502:physiology; D013006:Growth Hormone / Q000502:physiology; D006801:Humans; D055728:Primary Myelofibrosis / Q000175:diagnosis / Q000235:genetics / Q000503:physiopathology* / Q000628:therapy*; D011379:Prognosis; D013156:Splenectomy
D016207:Cytokines; D013006:Growth Hormone